CO5390076A1 - Composiciones farmaceuticas - Google Patents
Composiciones farmaceuticasInfo
- Publication number
- CO5390076A1 CO5390076A1 CO02092380A CO02092380A CO5390076A1 CO 5390076 A1 CO5390076 A1 CO 5390076A1 CO 02092380 A CO02092380 A CO 02092380A CO 02092380 A CO02092380 A CO 02092380A CO 5390076 A1 CO5390076 A1 CO 5390076A1
- Authority
- CO
- Colombia
- Prior art keywords
- mycophenolic acid
- mycophenolate
- salt
- tablet
- amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Una forma de dosis sólida que comprende una cantidad farmacológicamente efectiva de ácido micofenólico o sal de micofenolato, en donde el ácido micofenólico o la sal de micofenolato está presente en una cantidad desde alrededor del 20% hasta alrededor del 95% en peso con base en el peso total de la forma de dosis sólida. Una forma de dosis sólida de conformidad con la reivindicación 1, que es una tableta, la tableta comprende adicionalmenteb) aditivos farmacéuticamente aceptables adecuados para la preparación de tabletas por métodos de compresión en donde el ácido micofenólico o la sal de micofenolato está presente en una cantidad desde alrededor de 20% hasta alrededor de 90% en peso con base en el peso total de la tableta.Una forma de dosis sólida de conformidad con la reivindicación 1 ó 2, que contiene una sal de micofenolato de sodio en forma cristalina.Una forma de dosis sólida de conformidad con la reivindicación 1, que contiene ácido micofenólico o la sal de mono sodio de micofenolato cristalino en forma anhidra.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0124953.1A GB0124953D0 (en) | 2001-10-17 | 2001-10-17 | Organic Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5390076A1 true CO5390076A1 (es) | 2004-04-30 |
Family
ID=9924043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO02092380A CO5390076A1 (es) | 2001-10-17 | 2002-10-15 | Composiciones farmaceuticas |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US20050013859A1 (es) |
| EP (1) | EP1438040B2 (es) |
| JP (2) | JP2005508959A (es) |
| KR (1) | KR100671367B1 (es) |
| CN (1) | CN1310640C (es) |
| AR (2) | AR036813A1 (es) |
| AT (1) | ATE374023T1 (es) |
| AU (1) | AU2002338897B2 (es) |
| BR (1) | BR0213355A (es) |
| CA (1) | CA2460574A1 (es) |
| CO (1) | CO5390076A1 (es) |
| CY (1) | CY1107841T1 (es) |
| DE (1) | DE60222687T3 (es) |
| DK (1) | DK1438040T4 (es) |
| EC (2) | ECSP024341A (es) |
| ES (1) | ES2292819T5 (es) |
| GB (1) | GB0124953D0 (es) |
| HK (1) | HK1067861A1 (es) |
| HU (1) | HU231114B1 (es) |
| IL (2) | IL160968A0 (es) |
| MX (1) | MXPA04003636A (es) |
| MY (1) | MY139206A (es) |
| NO (1) | NO341804B1 (es) |
| NZ (1) | NZ532280A (es) |
| PE (1) | PE20030476A1 (es) |
| PL (2) | PL234541B1 (es) |
| PT (1) | PT1438040E (es) |
| RU (2) | RU2338528C2 (es) |
| SI (1) | SI1438040T2 (es) |
| TW (1) | TWI333861B (es) |
| WO (1) | WO2003032978A1 (es) |
| ZA (1) | ZA200401977B (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0124953D0 (en) | 2001-10-17 | 2001-12-05 | Novartis Ag | Organic Compounds |
| AR045957A1 (es) * | 2003-10-03 | 2005-11-16 | Novartis Ag | Composicion farmaceutica y combinacion |
| US7439373B2 (en) * | 2004-07-20 | 2008-10-21 | TEVA Gyógyszergyár Zártkörúen Múködö Részvénytársaság | Crystalline mycophenolate sodium |
| GB0419355D0 (en) * | 2004-08-31 | 2004-09-29 | Novartis Ag | Organic compounds |
| EP1917010A2 (en) * | 2005-02-08 | 2008-05-07 | Aspreva Pharmaceuticals SA | Compositions and methods for treating vascular, autoimmune and inflammatory diseases |
| WO2006086498A2 (en) * | 2005-02-08 | 2006-08-17 | Aspreva Pharmaceuticals Sa | Treatment of vascular, autoimmune and inflammatory diseases using low dosages of impdh inhibitors |
| AU2006297130B2 (en) * | 2005-09-30 | 2009-12-24 | Novartis Ag | DPP IV inhibitor for use in the treatment of autoimmune diseases and graft rejection |
| ES2403167T3 (es) * | 2005-12-21 | 2013-05-14 | Basf Se | Polivinilpirrolidona entrelazada finamente dividida como agente desintegrador de tabletas |
| AU2007214784A1 (en) * | 2006-02-13 | 2007-08-23 | Novartis Ag | High dosage of mycophenolic acid (MPA) |
| WO2008148742A2 (de) | 2007-06-06 | 2008-12-11 | Basf Se | Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten |
| JP2010529071A (ja) | 2007-06-06 | 2010-08-26 | ビーエーエスエフ ソシエタス・ヨーロピア | 速崩性錠剤製造のための医薬製剤 |
| BRPI0816231A2 (pt) * | 2007-08-13 | 2015-06-16 | Panacea Biotec Ltd | Composições de liberação prolongada compreendendo micofenolato de sódio e seus processos |
| EA201071035A1 (ru) * | 2008-03-05 | 2011-04-29 | Панацеа Биотек Лимитед | Фармацевтические композиции модифицированного высвобождения, содержащие микофенолат, и способ их получения |
| WO2010004435A2 (en) * | 2008-07-09 | 2010-01-14 | Aspreva International Ltd. | Formulations for treating eye disorders |
| US20110086102A1 (en) * | 2009-10-13 | 2011-04-14 | Teva Pharmaceutical Industries Ltd. | Delayed release compositions |
| EA201270544A1 (ru) * | 2009-10-13 | 2012-09-28 | Тева Фармасьютикал Индастриз Лтд. | Композиции с отсроченным высвобождением |
| WO2011051967A2 (en) * | 2009-10-23 | 2011-05-05 | Alkem Laboratories Ltd | Pharmaceutical compositions comprising mycophenolate and processes for preparing thereof |
| GB201100786D0 (en) | 2011-01-18 | 2011-03-02 | Ems Sa | Pharmaceutical compositions of immunosuppressants |
| CN102793658A (zh) * | 2012-08-23 | 2012-11-28 | 无锡福祈制药有限公司 | 一种含有麦考酚酸或麦考酚酸盐的骨架型制剂及其包衣片 |
| CN103845323B (zh) * | 2012-11-30 | 2018-02-02 | 重庆华邦制药有限公司 | 麦考酚酸及其盐肠溶制剂和制备方法 |
| WO2014167442A1 (en) | 2013-03-26 | 2014-10-16 | Wockhardt Limited | Pharmaceutical compositions comprising mycophenolic acid or salts thereof |
| CN106727403A (zh) * | 2017-01-03 | 2017-05-31 | 无锡福祈制药有限公司 | 一种麦考酚钠肠溶片及其制备方法 |
| AU2018236225B2 (en) * | 2017-03-13 | 2023-11-30 | Okava Pharmaceuticals, Inc. | Methods and compositions for delivering mycophenolic acid active agents to non-human mammals |
| BR112020024643A2 (pt) | 2018-06-06 | 2021-03-02 | Metavant Sciences Gmbh | método de tratamento de pré-diabetes ou diabetes mellitus tipo 1 ou tipo 2, método de melhoria do controle glicêmico em um sujeito tendo pré-diabetes ou diabetes tipo 1 ou tipo 2, imeglimina para uso em um método para tratamento de pré-diabetes ou diabetes mellitus tipo 1 ou tipo 2 de um sujeito, imeglimina para uso em um método para melhoria do controle glicêmico em um sujeito tendo pré-diabetes ou diabetes tipo 1 ou tipo 2, uso de imeglimina para a fabricação de um medicamento para o tratamento de um sujeito tendo pré-diabetes ou diabetes mellitus tipo 1 ou tipo 2 e uso de imeglimina para a fabricação de um medicamento para melhoria do controle glicêmico em um sujeito tendo pré-diabetes ou diabetes tipo 1 ou tipo 2 |
| BR112020025112A2 (pt) | 2018-06-14 | 2021-03-23 | Poxel | comprimido revestido por película e processo para a fabricação do comprimido revestido por película |
| RU2723255C2 (ru) * | 2018-11-14 | 2020-06-09 | Общество с ограниченной ответственностью "Изварино Фарма" | Экструдат с микофенолятом натрия для получения пероральной твердой лекарственной формы |
| WO2022162088A2 (en) * | 2021-01-28 | 2022-08-04 | Priothera Sas | Methods of treatment with s1p receptor modulators |
| EP4346790A1 (en) * | 2021-05-26 | 2024-04-10 | The Texas A&M University System | Biodegradable mucoadhesive pharmaceutical formulations and methods thereof |
| CN117442580B (zh) * | 2023-12-21 | 2024-04-05 | 泊诺(天津)创新医药研究有限公司 | 一种高生物利用度麦考酚钠肠溶片及其制备方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1157099A (en) * | 1966-09-27 | 1969-07-02 | Ici Ltd | Fermentation Process |
| GB1157100A (en) † | 1966-09-27 | 1969-07-02 | Ici Ltd | Pharmaceutical Compositions |
| GB1203328A (en) * | 1968-06-04 | 1970-08-26 | Ici Ltd | Pharmaceutical compositions |
| US3880995A (en) * | 1973-05-14 | 1975-04-29 | Lilly Co Eli | Treatment of arthritis with mycophenolic acid and derivatives |
| JPS56127093A (en) * | 1980-03-10 | 1981-10-05 | Ajinomoto Co Inc | Preparation of mycophenolic acid |
| US4725622A (en) * | 1986-01-23 | 1988-02-16 | Syntex (U.S.A.) Inc. | Mycophenolic acid derivatives in the treatment of rheumatoid arthritis |
| US4959387A (en) * | 1986-01-23 | 1990-09-25 | Syntex (U.S.A.) Inc. | Mycophenolic acid derivatives in the treatment of rheumatoid arthritis |
| US5177072A (en) * | 1987-01-30 | 1993-01-05 | Syntex (U.S.A.) Inc. | Treatment of autoimmune inflammatory, and psoriatic diseases with heterocyclic aminoalkyl esters of mycophenolic acid and derivatives |
| US4748173A (en) * | 1987-01-30 | 1988-05-31 | Syntex (U.S.A.) Inc. | Heterocyclic aminoalkyl esters of mycophenolic acid and derivatives thereof and pharmaceutical compositions |
| US4753935A (en) * | 1987-01-30 | 1988-06-28 | Syntex (U.S.A.) Inc. | Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions |
| AU3178293A (en) * | 1992-11-24 | 1994-06-22 | Syntex (U.S.A.) Inc. | Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis |
| WO1994012184A1 (en) * | 1992-11-24 | 1994-06-09 | Syntex (U.S.A.) Inc. | Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis |
| US5651983A (en) * | 1993-02-26 | 1997-07-29 | The Procter & Gamble Company | Bisacodyl dosage form for colonic delivery |
| BR9405836A (pt) * | 1993-02-26 | 1996-01-16 | Procter & Gamble | Forma de dosagem de bisacodil |
| US5656290A (en) * | 1993-02-26 | 1997-08-12 | The Procter & Gamble Company | Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery |
| US5843479A (en) * | 1993-02-26 | 1998-12-01 | The Procter & Gamble Company | Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery |
| US5455045A (en) * | 1993-05-13 | 1995-10-03 | Syntex (U.S.A.) Inc. | High dose formulations |
| ES2248793T3 (es) * | 1993-10-01 | 2006-03-16 | Roche Palo Alto Llc | Suspensiones orales de alta dosis de mofetil micofenolato. |
| AU7961094A (en) * | 1993-10-19 | 1995-05-08 | Procter & Gamble Company, The | Picosulphate dosage form |
| US5514663A (en) * | 1993-10-19 | 1996-05-07 | The Procter & Gamble Company | Senna dosage form |
| US5482718A (en) * | 1994-03-23 | 1996-01-09 | Hoffmann-La Roche Inc. | Colon-targeted delivery system |
| US5686106A (en) * | 1995-05-17 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form for colonic delivery |
| ID18663A (id) * | 1996-04-12 | 1998-04-30 | Novartis Ag | Komposisi farmasi berlapis enterik |
| ATE474590T1 (de) * | 1999-05-10 | 2010-08-15 | Paolo Brenner | Kombination von immunsuppressiven substanzen zur behandlung oder vorbeugung von transplantat abstossungen |
| HUP9903226A2 (en) * | 1999-09-23 | 2002-08-28 | Gyogyszerki | Process for producing mycophenolic acid and derivatives thereof |
| AU2000233225A1 (en) * | 2000-02-29 | 2001-09-12 | Biocon India Limited | Manufacture and purification of mycophenolic acid |
| GB0124953D0 (en) | 2001-10-17 | 2001-12-05 | Novartis Ag | Organic Compounds |
| GB0301259D0 (en) | 2003-01-20 | 2003-02-19 | Novartis Ag | Organic compounds |
-
2001
- 2001-10-17 GB GBGB0124953.1A patent/GB0124953D0/en not_active Ceased
-
2002
- 2002-10-15 PE PE2002001013A patent/PE20030476A1/es not_active Application Discontinuation
- 2002-10-15 CO CO02092380A patent/CO5390076A1/es not_active Application Discontinuation
- 2002-10-15 AR ARP020103852A patent/AR036813A1/es not_active Application Discontinuation
- 2002-10-15 TW TW091123694A patent/TWI333861B/zh not_active IP Right Cessation
- 2002-10-16 KR KR1020047005588A patent/KR100671367B1/ko active IP Right Review Request
- 2002-10-16 BR BRPI0213355-5A patent/BR0213355A/pt active Search and Examination
- 2002-10-16 ES ES02777314T patent/ES2292819T5/es not_active Expired - Lifetime
- 2002-10-16 PL PL367738A patent/PL234541B1/pl unknown
- 2002-10-16 IL IL16096802A patent/IL160968A0/xx unknown
- 2002-10-16 MY MYPI20023865A patent/MY139206A/en unknown
- 2002-10-16 CA CA002460574A patent/CA2460574A1/en not_active Abandoned
- 2002-10-16 CN CNB028198611A patent/CN1310640C/zh not_active Expired - Fee Related
- 2002-10-16 DE DE60222687.2T patent/DE60222687T3/de not_active Expired - Lifetime
- 2002-10-16 MX MXPA04003636A patent/MXPA04003636A/es active IP Right Grant
- 2002-10-16 WO PCT/EP2002/011589 patent/WO2003032978A1/en active IP Right Grant
- 2002-10-16 US US10/492,289 patent/US20050013859A1/en not_active Abandoned
- 2002-10-16 PL PL415001A patent/PL415001A1/pl unknown
- 2002-10-16 HU HU0600451A patent/HU231114B1/hu unknown
- 2002-10-16 SI SI200230646T patent/SI1438040T2/sl unknown
- 2002-10-16 DK DK02777314.2T patent/DK1438040T4/da active
- 2002-10-16 JP JP2003535782A patent/JP2005508959A/ja active Pending
- 2002-10-16 EP EP02777314.2A patent/EP1438040B2/en not_active Expired - Lifetime
- 2002-10-16 RU RU2004115332/15A patent/RU2338528C2/ru not_active IP Right Cessation
- 2002-10-16 NZ NZ532280A patent/NZ532280A/en not_active IP Right Cessation
- 2002-10-16 AU AU2002338897A patent/AU2002338897B2/en not_active Expired
- 2002-10-16 AT AT02777314T patent/ATE374023T1/de active
- 2002-10-16 PT PT02777314T patent/PT1438040E/pt unknown
- 2002-11-19 EC EC2002004341A patent/ECSP024341A/es unknown
- 2002-11-19 EC EC2002004342A patent/ECSP024342A/es unknown
-
2004
- 2004-03-11 ZA ZA200401977A patent/ZA200401977B/en unknown
- 2004-03-18 IL IL160968A patent/IL160968A/en active IP Right Grant
- 2004-05-03 NO NO20041785A patent/NO341804B1/no not_active IP Right Cessation
-
2005
- 2005-01-07 HK HK05100153A patent/HK1067861A1/xx not_active IP Right Cessation
-
2007
- 2007-08-13 RU RU2007130786/15A patent/RU2381026C2/ru not_active IP Right Cessation
- 2007-12-19 CY CY20071101618T patent/CY1107841T1/el unknown
-
2009
- 2009-01-23 JP JP2009012781A patent/JP2009137996A/ja active Pending
-
2010
- 2010-05-03 US US12/772,608 patent/US20100210717A1/en not_active Abandoned
-
2012
- 2012-05-04 AR ARP120101574A patent/AR085778A2/es not_active Application Discontinuation
- 2012-05-29 US US13/482,003 patent/US20120237601A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5390076A1 (es) | Composiciones farmaceuticas | |
| HRP20160327T1 (hr) | Čvrsti dozirni oblici fentanila s poboljšanom bukalnom apsorpcijom | |
| EA200500088A1 (ru) | Трициклические модуляторы ядерного рецептора стероидного гормона | |
| NO20062004L (no) | Forlenget frigjoring farmasoytiske blandinger omfattene aplindor og derivater derav | |
| HK1076605A1 (en) | Formulations | |
| AR084101A2 (es) | Comprimido de carga de droga alta y proceso para su preparacion | |
| BRPI0508833A (pt) | formulações galênicas de compostos orgánicos | |
| UY30537A1 (es) | Formulaciones de flibanserina y metodo para fabricarlas | |
| ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
| BRPI0413756A (pt) | composto, métodos para tratar ou evitar espasticidade ou um sintoma de espasticidade, doença de refluxo gastro-esofágico, vìcio em droga, vìcio em ou abuso de álcool, ou vìcio em ou abuso de nicotina, e tosse ou êmese em um paciente, e, composição farmacêutica | |
| BR0207880A (pt) | Formulação farmacêutica, processo para preparação da mesma e uso de formulação sólida | |
| AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
| RU2008103617A (ru) | Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза | |
| UA116334C2 (uk) | Тверді форми дозування бендамустину | |
| CO6150126A2 (es) | Formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina | |
| ECSP034826A (es) | Método para fabricar una composición farmacéutica de dosis baja | |
| PA8580601A1 (es) | Composicion farmaceutica de altas dosis | |
| AR095159A2 (es) | Una composición farmacéutica en forma de cápsula para administración oral | |
| BR0114100A (pt) | Formulações de liberação controlada para administração oral | |
| BR0311642A (pt) | Formulação de divalproex de sódio de liberação aumentada | |
| CL2004000858A1 (es) | Peptidos que comprende una region acida, una lipofilica o aromatica y una basica, que participan en transporte inverso de colesterol, composicion farmaceutica que los contienen, util para el tratamiento o prevencion de hipercolesterolemia y/o aterosc | |
| MX2024006975A (es) | Inhibidor de cdk9 y uso del mismo. | |
| GT200000087A (es) | Formas polimorfas de un citrato de azabiciclo(2.2.2) octan - 3 - amina y sus composiciones farmaceuticas. | |
| BR0313175A (pt) | Formulações farmacêuticas compreendendo combinações de epinastina, pseudoefedrina e metilefedrina | |
| CY1108846T1 (el) | Βελτιωμενη φαρμακευτικη συνθεση που περιεχει αναστολεα ace και μεθοδος για την παρασκευη της |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |